Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494516 | 0.94 | KISS1R (0.73) | KISS1RNPBWR1 | |
| SCHEMBL29657318 | 0.90 | KISS1R (0.78) | KISS1R | |
| SCHEMBL15930214 | 0.90 | KISS1R (0.78) | KISS1R | |
| Kisspeptin-10 SCHEMBL29376534 | 0.90 | KISS1R (0.77) | KISS1R | |
| Kisspeptin-10 SCHEMBL20865531 | 0.90 | KISS1R (0.77) | KISS1R | |
| SCHEMBL29379050 | 0.90 | KISS1R (0.77) | KISS1R | |
| SCHEMBL29872723 | 0.90 | KISS1R (0.71) | KISS1RNPBWR1 | |
| SCHEMBL30530852 | 0.90 | KISS1R (0.77) | KISS1R | |
| Kisspeptin-10 SCHEMBL15930211 | 0.90 | KISS1R (0.77) | KISS1R | |
| SCHEMBL17345398 | 0.90 | KISS1R (0.77) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2379053-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | KISS1R 1427/4885NPBWR1 1210/4885 |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | KLK3, SHBG, SERPINA3 | KISS1R 901/4885NPBWR1 1725/4885 |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | KISS1R 119/4885NPBWR1 566/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | KISS1R 1427/4885NPBWR1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.